Prosecution Insights
Last updated: May 29, 2026
Application No. 18/547,596

ANTIMICROBIAL WET WIPES

Final Rejection §103
Filed
Aug 23, 2023
Priority
Mar 31, 2021 — provisional 63/168,589 +1 more
Examiner
MERCIER, MELISSA S
Art Unit
1615
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Kimberly-Clark Worldwide Inc.
OA Round
4 (Final)
72%
Grant Probability
Favorable
5-6
OA Rounds
0m
Est. Remaining
78%
With Interview

Examiner Intelligence

Grants 72% — above average
72%
Career Allowance Rate
856 granted / 1190 resolved
+11.9% vs TC avg
Moderate +6% lift
Without
With
+5.9%
Interview Lift
resolved cases with interview
Typical timeline
2y 10m
Avg Prosecution
34 currently pending
Career history
1236
Total Applications
across all art units

Statute-Specific Performance

§101
0.9%
-39.1% vs TC avg
§103
60.9%
+20.9% vs TC avg
§102
6.6%
-33.4% vs TC avg
§112
6.4%
-33.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1190 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on November 5, 2025 has been entered. Status of Application Receipt of Applicant’s remarks and amended claims filed on November 5, 2025 is acknowledged. Claims 1, 3, 5-7, 9-11, 14-16, and 18-19 are pending in this application. Claims 2, 4, 8, 12-13, 17, and 20 have been cancelled. Claim 9 has been amended. Claims 10-11, 14-16, and 18-19 remain withdrawn from consideration per the restriction requirement dated March 7, 2025. Withdrawn Objections/Rejections Claim Objections The objection to claim 9 under 37 CFR 1.75 as being a substantial duplicate of claim 1 has been withdrawn in view of the amendment to the claim to recite “the wet wipe composition is further incorporated into a consumer product selected from the group consisting of hand wipes, face wipes. baby wipes, cosmetic wipes, feminine hygiene wipes, cooling wipes, cleaning wipes. flushable wipes, and combinations thereof.” Claim Rejections - 35 USC § 103 The rejection of claims 1, 3, 5-7, and 9 under 35 U.S.C. 103 as being unpatentable over Fujimura et al. (JP 2016165431A) in view of Thom et al. (Microbial Growth Modification by Compressed Gases and Hydrostatic Pressure, Applied and Environmental Microbiology, April 1984, p780-787) has been withdrawn in view of the arguments that N2O is not an inert gas. Newly Applied Rejections Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claims 1, 3, 5-7, and 9 are rejected under 35 U.S.C. 103 as being unpatentable over Fujimura et al. (JP 2016165431A) in view of Yu et al. (High-Pressure Carbon Dioxide Used for Pasteurization in Food Industry, Food Engineering Reviews (2020) 12:364-380). Fujimura discloses a wipe cleaning disinfection sheet containing nanobubble water that can be used for an infant whose skin is delicate and an elderly person whose skin is weak without adding a cleaning agent or a bactericidal agent to a nonwoven fabric sheet (abstract). The nanobubbles may be produced by pressurizing and introducing the water to be treated and the gas directly into the static fluid mixer (description of embodiments). Preservatives MAY be added, but are not disclosed as a required element (description of embodiments). Regarding claim 2, a nonwoven fabric sheet is a wet wipe substrate. Regarding claim 3, the nanobubbles can be nitrogen, oxygen, carbon dioxide, helium, and mixtures thereof (description of embodiments). Regarding claims 6-7, Fujimura discloses 0.2L of carbon dioxide dissolved in 1 L of water (Examples), which is 0.009 mol/L. It is the position of the Examiner that 0.009 is “about 0.01” as recited in the instant claims. Regarding claim 9, the substrate including sheets which can be used to clean infant skin (baby wipes) or as cleansing wipes (Solution). Fujimura does not disclose the pressure at which the gas is added to the wet wipe formulation. Yu discloses the bactericidal effect of high pressure carbon dioxide (HPCD) has been known for many years (abstract). High-pressure carbon dioxide (HPCD) is a type of nonthermal pasteurization that applies pressurized CO2, at between 0.1 MPa (1 bar) and 50 MPa (500 bar). HPCD uses less sophisticated equipment, since most microbes can be inactivated at under 50 MPa. HPCD possesses great potential as a novel, nonthermal pasteurization technology, and the bactericidal effects on various microorganisms (High Pressure Carbon Dioxide). Regarding claim 5, it is noted that 1 bar is 14.5 PSI, therefore Yu discloses HPCD is done between 14.5 PSI to 7251.9 PSI. It would have been obvious to one of ordinary skill in the art prior to the effective filing date of the invention to have used the teachings of Yu in the formulation of Fujimura since Yu is drawn to treatment of food stuffs, the same technique and process can be adapted to topical cosmetic treatment solutions. Applicant’s attention is directed to MPEP 2141.01(a) which discloses in order for a reference to be proper for use in an obviousness rejection under 35 USC 103, the reference must be analogous art to the claimed invention. In re Bigio, 381 F.3d 1320, 1325, 72 USPQ2d 1209, 1212 (Fed. Cir. 2004). A reference is analogous art to the claimed invention if: (1) the reference is from the same field of endeavor as the claimed invention (even if it addresses a different problem); or (2) the reference is reasonably pertinent to the problem faced by the inventor (even if it is not in the same field of endeavor as the claimed invention). Note that "same field of endeavor" and "reasonably pertinent" are two separate tests for establishing analogous art; it is not necessary for a reference to fulfill both tests in order to qualify as analogous art. See Bigio, 381 F.3d at 1325, 72 USPQ2d at 1212. In the instant case, Yu was attempting to provide bactericidal effects on foodstuffs, whereas the instant claims are attempting to provide bactericidal effects on cosmetic formulations (Instant specification, paragraph 0023). Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to MELISSA S MERCIER whose telephone number is (571)272-9039. The examiner can normally be reached M-F 6:30 am to 4 pm EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Robert A Wax can be reached on 571-272-0623. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MELISSA S MERCIER/Primary Examiner, Art Unit 1615
Read full office action

Prosecution Timeline

Show 2 earlier events
May 22, 2025
Response Filed
Aug 05, 2025
Final Rejection mailed — §103
Oct 06, 2025
Response after Non-Final Action
Nov 05, 2025
Request for Continued Examination
Nov 06, 2025
Response after Non-Final Action
Nov 17, 2025
Non-Final Rejection mailed — §103
Feb 02, 2026
Response Filed
May 27, 2026
Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12636271
NEW COMBINATION COMPRISING N-ACETYL-L-CYSTEINE AND ITS USE
3y 8m to grant Granted May 26, 2026
Patent 12636250
MICRONEEDLE ARRAY PATCHES (MAPS), SYSTEMS, AND METHODS FOR MANUFACTURING AND USING SAME
1y 2m to grant Granted May 26, 2026
Patent 12622996
WOUND DRESSING COMPOSITIONS AND USES THEREOF
5y 1m to grant Granted May 12, 2026
Patent 12622881
WATER-SOLUBLE TOPICAL OPHTHALMIC PREPARATION CONTAINING LUTEIN AND PRODUCTION METHOD THEREOF
2y 8m to grant Granted May 12, 2026
Patent 12616686
DONEPEZIL ORAL FILMS
2y 9m to grant Granted May 05, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

5-6
Expected OA Rounds
72%
Grant Probability
78%
With Interview (+5.9%)
2y 10m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 1190 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month